Alnylam announces publication of results from apollo-b phase 3 study of patisiran in patients with the cardiomyopathy of attr amyloidosis in the new england journal of medicine

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that results from the apollo-b phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (attr) amyloidosis were published online in the new england journal of medicine (nejm). the data reported in the apollo-b phase 3 study publication demonstrate that patisiran, an rnai therapeutic targeting transthyretin (ttr),.
ALNY Ratings Summary
ALNY Quant Ranking